Clinical Trials Logo

Clinical Trial Summary

Research in test tubes suggests that may affect cytochrome P450 2D6 (CYP2D6), an important enzyme that is responsible for eliminating many drugs that cancer patients need to take, including dextromethorphan. The purpose of this study is to test the impact of PF-00299804 on the activity of CYP2D6, and how the human body handles dextromethorphan.


Clinical Trial Description

To assess the effect of repeated dosing with 45 mg QD PF-00299804 on the pharmacokinetics of dextromethorphan, a CYP2D6 probe, in cancer patients with advanced malignant solid tumors. ;


Study Design

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label


Related Conditions & MeSH terms


NCT number NCT00728468
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 1
Start date September 2008
Completion date July 2014

See also
  Status Clinical Trial Phase
Completed NCT00445458 - A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer Phase 1/Phase 2
Completed NCT00768469 - Study Evaluating Safety And Tolerability, Solid Tumor Phase 1
Recruiting NCT04226066 - Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT04908046 - A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT06464055 - A Study of GQ1010 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06231550 - A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors Phase 1
Not yet recruiting NCT05383703 - Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor Phase 1
Recruiting NCT05773937 - A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors Phase 1
Completed NCT04328506 - Bioequivalency Study of CM082 Tablet in Healthy Volunteers Phase 1
Recruiting NCT05886374 - A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors Phase 1
Completed NCT00958724 - Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors Phase 1
Not yet recruiting NCT05949775 - Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors N/A
Terminated NCT02045095 - A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors Phase 1
Completed NCT00884845 - Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT05277454 - Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT Phase 1
Active, not recruiting NCT03792958 - Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors Phase 1
Withdrawn NCT00997360 - Study of PKI-179 Administered Orally to Subjects With Solid Tumors Phase 1
Completed NCT04126668 - A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers Phase 1
Recruiting NCT05338957 - A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. Phase 1/Phase 2
Recruiting NCT03047811 - The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors N/A